Screener
Eli Lilly LLY Sales Rebates and Discounts
Sales Rebates and Discounts at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept lly:SalesRebatesAndDiscounts.
The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 2:40 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000059478-26-000081
| Assets | June 30, 2026 / (Unaudited) | December 31, 2025 |
|---|---|---|
| Short-term borrowings and current maturities of long-term debt | $7,050 | $1,635 |
| Accounts payable | 6,112 | 5,379 |
| Employee compensation | 1,798 | 2,375 |
| Sales rebates and discounts | 21,122 | 17,382 |
| Other current liabilities | 11,659 | 8,457 |
| Total current liabilities | 47,741 | 35,228 |
| Noncurrent Liabilities | ||
| Long-term debt | 47,858 | 40,868 |
Item 1. Financial Statements
FAQ
- What is Eli Lilly's sales rebates and discounts?
- Eli Lilly (LLY) reported sales rebates and discounts of $21.12B in Q2 2026.
- How has Eli Lilly's sales rebates and discounts changed year-over-year?
- Eli Lilly's sales rebates and discounts increased by 45.3% year-over-year, from $14.54B to $21.12B.
- What is the long-term trend for Eli Lilly's sales rebates and discounts?
- Over 5 years (2020 to 2025), Eli Lilly's sales rebates and discounts has grown at a 24.3% compound annual growth rate (CAGR), from $5.85B to $17.38B.
- What does sales rebates and discounts mean?
- Accrued liabilities representing estimated rebates, chargebacks, and discounts owed to wholesalers, pharmacy benefit managers, and government programs. In the pharmaceutical industry, this is a critical contra-revenue adjustment that reflects the difference between gross and net pricing. It is essential for understanding the true realized revenue of drug products.
Ask your AI about Eli Lilly's sales rebates and discounts.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude